期刊文献+

临床药师参与处置伏立康唑致血液系统肿瘤患者视觉障碍的临床实践 被引量:5

Practice of clinical pharmacists participating in treatment of visual impairment caused by voriconazole in a patient of multiple myeloma
下载PDF
导出
摘要 目的通过临床药师参与一例血液系统肿瘤并粒细胞缺乏患者长期服用伏立康唑片剂后出现视觉障碍不良反应的临床实践过程,探讨临床药师的服务模式、药学监护内容及临床药师应具备的基础知识和技能。方法对病例的病史、用药史、当前用药进行全面系统回顾,利用药品不良反应因果关系判别方法分析患者反应与用药间相互关系,考察药物浓度影响因素,提出改进用药的建议。结果医师接受药学建议,减少合并用药奥美拉唑的剂量以减轻肝药酶抑制,降低对伏立康唑浓度干扰。10 d后患者视觉障碍症状缓解。结论临床药师应具备灵活运用所学药学知识的能力,能通过独立思考判断与评估用药后可能产生的效益及风险,制定药学监护计划,减少或避免药源性损伤。 Objective To discuss the service mode, contents of pharmaceutical care and the basic knowledge and skills that a clinical pharmacist should master by participating in treatment of visual impairment caused by voriconazole in a patient of multiple mye- loma. Methods The case history, past medication and ongoing administration of the patient of multiple myeloma were systematically analyzed to find out the relationship between the adverse reaction and the combined medication. Then rational advice was given accord- ing to the pharmacological characteristics and drug concentration of voriconazole. Results The physician accepted the advice and re- duced the dose of omeprazole for less suppression of hepatic drug metabolizing enzyme and fewer disturbances on dose of voriconazole. Ten days later visual impairment of the patient was improved. Conclusion Clinical pharmacists should be good at flexibly using phar- macological knowledge, evaluating the effects and risks of medication and planning for pharmaceutical care to reduce or avoid subse- quent drug impairment.
出处 《药学实践杂志》 CAS 2013年第4期307-309,共3页 Journal of Pharmaceutical Practice
关键词 伏立康唑 不良反应 临床药师 voriconazole adverse reaction clinical pharmacist
  • 相关文献

参考文献5

二级参考文献25

  • 1曹永兵,张磊,王彦,姜远英.伏立康唑及其临床应用[J].中国新药与临床杂志,2005,24(4):330-332. 被引量:48
  • 2陈丽娟.HPLC测定人血浆中伊曲康唑的浓度[J].华西药学杂志,2006,21(3):293-295. 被引量:10
  • 3PFALLER MA,ZHANG J,MESSER SA,et al. In vitro activities of voriconazole, ftubonazol,and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother, 1999,43 ( 1 ) : 169 - 171. 被引量:1
  • 4SUTTON DA, SANCHE SE, REVANKAR SG, et al. In vitro amplhoteriein B resistance in clinical isolates of Aspergillus terreus,with a head-to-head comparison to voriconazole. J ClinMicro2biol, 1999,37 (7) :2343. 被引量:1
  • 5DENNING DW,R IBAUD P,MILP IED N,et al. Efficacy and safety of vorieonazole in the treatment of acute invasive aspergillosis. Clin Infect Dis,2002,34(5) :563-571. 被引量:1
  • 6Singh N. Trends in the epidemiology of opportunistic fungal infections:predisposing factors and the impact of antimicrobiaI use practices[J]. Clin Infect Dis,2001,33(15) : 1692- 1696. 被引量:1
  • 7Denning D W,Tueker R M,Hanson L H,et al. Treatment of invasive aspergillosis with itraconazole[J]. Am J Med, 1989, 86(6 Pt2) :791-800. 被引量:1
  • 8Tucker R M,Denning D W,Arathoon E G,et al. Itraconazote therapy for nonmeningeal coccidioidomycosis: clinical and lahoratory observations [J]. J Am Acad Dermatol, 1990, 23(3Pt 2):593 -601. 被引量:1
  • 9Denning D W, Tucker R M, Hanson I. H, et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis[J].Arch Intern Med,1989,149(10) :2301-2308. 被引量:1
  • 10Tricot G,Joosten E, Boogaerts M A, et al. Retoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies[J].Rev Infect Dis, 1987,9(Suppl 1):S94-S99. 被引量:1

共引文献70

同被引文献82

引证文献5

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部